Skip to main content

Kiniksa Pharmaceuticals International, plc

KNSA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001730430

In the last 90 days, Kiniksa Pharmaceuticals International, plc insiders filed 0 open-market purchases and 2 sales; 267 institutions reported holding it in 13F filings for Q2 2026, worth $2.99B in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Kiniksa Pharmaceuticals International, plc changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of KNSA: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders105102−3
Shares29.0M28.9M−190.6K (−0.7%)
Value$537.6M$402.0M−$135.7M (−25.2%)

New holders (14)

Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to KNSA in Q2 2021
InstitutionSharesValue% of portfolio
Balyasny Asset Management LLC400,296$5.58M0.03%
Two Sigma Investments, LP49,232$686.0K0.00%
Hennion & Walsh Asset Management, Inc.43,116$601.0K0.03%
Squarepoint Ops LLC28,744$400.0K0.00%
Birchview Capital, LP20,000$279.0K0.17%
State Board of Administration of Florida Retirement System14,378$200.0K0.00%
Price T Rowe Associates Inc13,231$184.0K0.00%
Invesco Ltd.10,985$153.0K0.00%
Cowen and Company, LLC10,000$139.0K0.01%
Quantbot Technologies LP2,754$38.0K0.00%
Advisory Services Network, LLC701$10.0K0.00%
Mirae Asset Global Investments Co., Ltd.526$7.00K0.00%
Beck Bode, LLC300$4.00K0.00%
State of Wyoming235$3.00K0.00%

Sold out (17)

Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q1 2021 and filed for Q2 2021 without it.